Amgen Inc. (NASDAQ:AMGN) is one of the best stem cell therapy stocks to buy. Canaccord initiated coverage of Amgen Inc.

Learn more In the latest trading session, Amgen (AMGN) closed at $344.55, marking a -1.17% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day.

Amgen AMGN will report first-quarter 2026 results on April 30 after market close. In the last reported quarter, the company's ...

In the latest close session, Amgen (AMGN) was up +1.69% at $355.30. This move outpaced the S&P 500's daily gain of 1.2%. Elsewhere, the Dow gained 1.79%, while the tech-heavy Nasdaq added 1.52%. Prior ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

In this article, we will list the 5 Best Stem Cell Therapy Stocks to Buy. If you wish to see the methodology behind the ...

Bristol Myers Squibb BMY and Amgen AMGN are among the largest global biotechnology companies with broad and diverse portfolios. Bristol Myers Squibb is focused on discovering, developing and ...

Amgen Inc. (NASDAQ:AMGN) is one of the 7 Most Profitable Value Stocks to Buy Right Now. Amgen Inc. (NASDAQ:AMGN) is one of the most profitable value stocks to buy right now. On April 6, Amgen ...

Looking ahead to 2030, our model projects AMGN could trade at an average price of $537.89, with a potential range between $403.41 and $672.36. This represents a potential 57.0% return from today's ...